Tabrecta

Active Ingredient(s): Capmatinib Hydrochloride
FDA Approved: * May 6, 2020
Pharm Company: * NOVARTIS PHARM
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tabrecta Overview

Capmatinib, sold under the brand name Tabrecta, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.[1][2][3] The most common adverse reactions are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.[1][4] ...

Read more Tabrecta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Capmatinib

Recent Tabrecta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Tabrecta: (2 results)

Sorted by National Drug Code

• 0078-0709 Tabrecta 150 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
• 0078-0716 Tabrecta 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation

Other drugs which contain Capmatinib Hydrochloride or a similar ingredient: (1 result)

• CAPMATINIB